We wish to inform you that Board of Directors in its meeting held today i.e., November 07, 2025 approved the unaudited financial results for the quarter and half year ended September 30, ....
BAYERCROP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Smallcap 250 and 3.2 pts more than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bayer CropScience's Board approved unaudited results for the quarter and half year ended September 30, 2025. Q2 FY26 revenue from operations fell about 10.6% YoY to Rs. 15,534 Million (from Rs. 17,382 Million in Q2 FY25), though H1 revenue grew modestly to Rs. 34,680 Million (up ~2.9% YoY). Profit after tax rose to Rs. 1,527 Million in Q2 (up ~12% YoY) and Rs. 4,314 Million in H1 (up ~10.5% YoY), with H1 EPS at Rs. 95.99. The Board declared an interim dividend of Rs. 90 per share (total payout ~Rs. 4,045 Million) with record date November 14, 2025 and payment on December 3, 2025. Operating cash flow remained negative at -Rs. 349 Million in H1, though better than -Rs. 856 Million in the year-ago period. The limited review report from Deloitte Haskins & Sells LLP is unqualified.
Shareholders benefit from a strong Rs. 90 interim dividend (90% on face value), signaling confidence and healthy cash returns despite a weak Q2 topline. Weak Q2 revenue and negative operating cash flow are watchpoints, but improving profit growth and a clean auditor report support near-term sentiment.